DK3849970T3 - Krystallinsk (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluormethoxy)benzyl)piperazin-1-carboxylat, sammensætninger og fremgangsmåder til anvendelse deraf - Google Patents

Krystallinsk (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluormethoxy)benzyl)piperazin-1-carboxylat, sammensætninger og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3849970T3
DK3849970T3 DK19778721.1T DK19778721T DK3849970T3 DK 3849970 T3 DK3849970 T3 DK 3849970T3 DK 19778721 T DK19778721 T DK 19778721T DK 3849970 T3 DK3849970 T3 DK 3849970T3
Authority
DK
Denmark
Prior art keywords
carbamoylpyridin
trifluormethoxy
piperazine
carboxylate
benzyl
Prior art date
Application number
DK19778721.1T
Other languages
Danish (da)
English (en)
Inventor
Lianfeng Huang
Nancy Tsou
Nicole Suzanne White
Jun Xu
Qun Zhang
Original Assignee
Celgene Corp
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Lundbeck La Jolla Research Center Inc filed Critical Celgene Corp
Application granted granted Critical
Publication of DK3849970T3 publication Critical patent/DK3849970T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK19778721.1T 2018-09-13 2019-09-12 Krystallinsk (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluormethoxy)benzyl)piperazin-1-carboxylat, sammensætninger og fremgangsmåder til anvendelse deraf DK3849970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3849970T3 true DK3849970T3 (da) 2024-09-30

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19778721.1T DK3849970T3 (da) 2018-09-13 2019-09-12 Krystallinsk (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluormethoxy)benzyl)piperazin-1-carboxylat, sammensætninger og fremgangsmåder til anvendelse deraf

Country Status (28)

Country Link
US (4) US11053199B2 (enExample)
EP (2) EP4434583B1 (enExample)
JP (1) JP7405840B2 (enExample)
KR (1) KR102844245B1 (enExample)
CN (3) CN118561814A (enExample)
AU (1) AU2019337623B2 (enExample)
BR (1) BR112021004340A2 (enExample)
CA (1) CA3112200A1 (enExample)
CL (1) CL2021000596A1 (enExample)
CO (1) CO2021003295A2 (enExample)
DK (1) DK3849970T3 (enExample)
EA (1) EA202190511A1 (enExample)
ES (1) ES2993173T3 (enExample)
FI (1) FI3849970T3 (enExample)
HR (1) HRP20241294T1 (enExample)
HU (1) HUE068147T2 (enExample)
IL (1) IL281276B2 (enExample)
LT (1) LT3849970T (enExample)
MA (1) MA53607B1 (enExample)
MX (1) MX2021002923A (enExample)
MY (2) MY210363A (enExample)
PL (1) PL3849970T3 (enExample)
PT (1) PT3849970T (enExample)
RS (1) RS65967B1 (enExample)
SG (1) SG11202102143RA (enExample)
SI (1) SI3849970T1 (enExample)
SM (1) SMT202400369T1 (enExample)
WO (1) WO2020056105A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019337623B2 (en) 2018-09-13 2024-12-05 Celgene Corporation Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1- carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
EP4335848A3 (en) 2017-03-13 2024-06-19 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
AU2019337623B2 (en) 2018-09-13 2024-12-05 Celgene Corporation Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1- carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
CN113227069A (zh) 2021-08-06
CO2021003295A2 (es) 2021-07-30
CN118561814A (zh) 2024-08-30
US12410133B2 (en) 2025-09-09
KR102844245B1 (ko) 2025-08-11
MY208901A (en) 2025-06-09
AU2019337623B2 (en) 2024-12-05
BR112021004340A2 (pt) 2021-05-25
US20230382861A1 (en) 2023-11-30
EP3849970B1 (en) 2024-07-03
AU2019337623A1 (en) 2021-05-13
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
MY210363A (en) 2025-09-13
PT3849970T (pt) 2024-09-25
PL3849970T3 (pl) 2025-01-07
EP4434583A2 (en) 2024-09-25
WO2020056105A9 (en) 2020-05-28
HUE068147T2 (hu) 2024-12-28
US11680046B2 (en) 2023-06-20
EP4434583A3 (en) 2024-11-20
JP2022500441A (ja) 2022-01-04
CL2021000596A1 (es) 2021-07-30
IL281276B1 (en) 2024-09-01
US20210363105A1 (en) 2021-11-25
CA3112200A1 (en) 2020-03-19
SG11202102143RA (en) 2021-04-29
EP4434583B1 (en) 2026-04-01
KR20210057789A (ko) 2021-05-21
EA202190511A1 (ru) 2021-07-05
WO2020056105A1 (en) 2020-03-19
MX2021002923A (es) 2021-09-08
IL281276A (en) 2021-04-29
US11053199B2 (en) 2021-07-06
MA53607B1 (fr) 2025-05-30
EP3849970A1 (en) 2021-07-21
MA53607A (fr) 2021-12-22
FI3849970T3 (fi) 2024-09-20
CN118530218A (zh) 2024-08-23
IL281276B2 (en) 2025-01-01
ES2993173T3 (en) 2024-12-23
SMT202400369T1 (it) 2024-11-15
US20260062384A1 (en) 2026-03-05
RS65967B1 (sr) 2024-10-31
CN113227069B (zh) 2024-11-05
US20200095201A1 (en) 2020-03-26
SI3849970T1 (sl) 2024-11-29
LT3849970T (lt) 2024-10-10

Similar Documents

Publication Publication Date Title
DK4075992T3 (da) Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf
DK3963021T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf
IL284223A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3906220T3 (da) Hidtil ukendt formulering til konstruktionsbindemiddel med lavt carbonindhold, fremgangsmåde til fremstilling heraf og konstruktionsmaterialer
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3784663T3 (da) Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
DK3788045T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
LT3687506T (lt) Pakeistieji benzofuranas, benzopirolas, benzotiofenas ir struktūriškai susiję komplemento inhibitoriai
IL284187A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
EP3896109A4 (en) CURABLE COMPOSITION
DK3817757T3 (da) Peptid-deficient mhc-klasse-i/chaperon-sammensætninger og fremgangsmåder
DK3947684T3 (da) Forbindelser og fremgangsmåder til at modulere ube3a-ats
DK3658553T3 (da) Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
EP3929260A4 (en) CURABLE COMPOSITION
DK3761779T3 (da) Elastisk struktur og tilsvarende fremgangsmåde til opsætning
DK3765440T3 (da) Fremgangsmåde til fremstilling af n-alkyl-nitratoethylnitraminer
DK4223886T3 (da) Sammensætninger og fremgangsmåder til stabilisering af mikro-rna
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
DK3953348T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3849970T3 (da) Krystallinsk (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluormethoxy)benzyl)piperazin-1-carboxylat, sammensætninger og fremgangsmåder til anvendelse deraf
DK3744416T3 (da) Fremgangsmåde og anlæg til syntese af metanol
DK4073051T3 (da) Fremgangsmåde og mellemstof til fremstilling af oxetan-2-ylmethanamin